DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Alcaftadineis the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Alcaftadine has forty-six patent family members in thirty countries.
There are six drug master file entries for alcaftadine. One supplier is listed for this compound.
Summary for alcaftadine
|Drug Master File Entries:||6|
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||47|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for alcaftadine|
|DailyMed Link:||alcaftadine at DailyMed|
Recent Clinical Trials for alcaftadine
Identify potential brand extensions & 505(b)(2) entrants
|Starx Research Center, LLC||Phase 4|
Pharmacology for alcaftadine
|Drug Class||Histamine-1 Receptor Antagonist |
|Mechanism of Action||Histamine H1 Receptor Antagonists |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
|Country||Patent Number||Estimated Expiration|
|European Patent Office||3150209||Start Trial|
|South Africa||200809327||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.